Legend Biotech (LEGN) Non-Current Assets (2019 - 2025)

Legend Biotech has reported Non-Current Assets for 7 years, with the latest figure at $486.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets rose 25.96% year-over-year to $486.6 million; the trailing twelve-month figure through Dec 2025 stood at $486.6 million (up 25.96% YoY), and the FY2025 full-year result was $486.6 million, up 25.96% from the prior year.
• Non-Current Assets for Q4 2025 stood at $486.6 million, up from $470.9 million in the prior quarter.
• The five-year high for Non-Current Assets was $486.6 million in Q4 2025, with the low at $140179.0 in Q1 2021.
• Historically, Non-Current Assets has averaged $305.0 million across 5 years, with a median of $340.7 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Assets jumped 155006.86% — and 2025, when it advanced 9.84%.
• Legend Biotech's Non-Current Assets stood at $169.6 million in 2021, then surged by 36.69% to $231.8 million in 2022, then surged by 51.31% to $350.8 million in 2023, then gained by 10.12% to $386.3 million in 2024, then climbed by 25.96% to $486.6 million in 2025.
• The last three Non-Current Assets figures came in at $486.6 million (Q4 2025), $470.9 million (Q3 2025), and $440.0 million (Q2 2025), per Business Quant data.